Previous 10 | Next 10 |
InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th InMed Pharmaceuticals invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com PR N...
InMed Pharmaceuticals (NASDAQ: INM) , a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol ("CBN"), will be a featured company in the upcoming Cannabis Industry Virtual Investor Conf...
Cannabis Executives Present: Cannabis Investor Conference September 8th & 9th Cannabis Executives Present: Cannabis Investor Conference September 8th & 9th Canada NewsWire Cannabis Company Executives share vision, answer questions live at VirtualInvestorC...
Cannabis Industry Investor Conference: Company Executives Present September 8th & 9th Cannabis Industry Investor Conference: Company Executives Present September 8th & 9th Cannabis Company Executives share vision, answer questions live at VirtualInvestorConferences.c...
The presentation highlighted the company’s INM-088 cannabinol topical eye drop to treat glaucoma InMed’s IntegraSyn is being used to help the company develop synthetic bioidentical rare cannabinoids in the lab, as most are only found in trace amounts in cannabis plants I...
Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids InMed Pharmaceutical has developed a trademarked platform called IntegraSyn that extracts five times the normally expected yields of cannabinoids fro...
InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids. The company is creating a pipeline of drug candidates to treat various diseases with high u...
InMed Pharmaceuticals (NASDAQ: INM) , a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced its plans to participate at the upcoming H.C. Wainwright Ophthalmology...
VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for ...
InMed announced a non-binding letter of intent to acquire BayMedica Inc. The move is designed to grow InMed’s market presence and strengthen its operations The two companies have had a reciprocal research collaboration that dates back to November 2020 InMed looks to capitaliz...
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
INM Stock Symbol:
NASDAQ Market:
InMed Pharmaceuticals Inc. Website:
InMed Pharmaceuticals (NASDAQ: INM) , a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's di...
Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30,...
Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a...